{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:26:05Z","timestamp":1791300365062,"version":"4.1.0"},"reference-count":70,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2004,2,15]]},"abstract":"<jats:p> Major risks conferred by BRCA1 and BRCA2 in women are for cancers of the breast, ovary, fallopian tube, and peritoneum. Male carriers of mutations in BRCA1 or BRCA2 are also susceptible to cancer; however, their risks remain poorly understood and their optimal clinical management has not yet been defined. This article reviews studies that estimate risk associated with mutations in BRCA1 or BRCA2, with a focus on the cancer sites most relevant to men. Male BRCA1 mutation carriers are at increased risk of cancers of the prostate and breast. Evidence supporting increased susceptibility to colon cancer is limited. In contrast to women, who have a greater lifetime risk of cancer with mutations of the BRCA1 gene, BRCA2 is the more important gene for men. The spectrum of cancers is wide for BRCA2 and some studies report that the overall cancer risk for male BRCA2 carriers exceeds the risk for female carriers. In particular, the relative risk to male BRCA2 mutation carriers is high before age 65 years, largely attributable to breast, prostate, and pancreatic cancers. BRCA2 mutation carriers are also at risk of stomach cancer and melanoma (of the skin and eye). Additional research into risks to male BRCA1 or BRCA2 mutation carriers is necessary, specifically to determine the magnitude of excess cancer risk among BRCA2 carriers and to increase our understanding of the basis for the observed site-specificity in cancer development. <\/jats:p>","DOI":"10.1200\/jco.2004.05.055","type":"journal-article","created":{"date-parts":[[2004,2,14]],"date-time":"2004-02-14T02:18:29Z","timestamp":1076725109000},"page":"735-742","source":"Crossref","is-referenced-by-count":323,"title":["Cancer Risks for Male Carriers of Germline Mutations in <i>BRCA1<\/i> or <i>BRCA2<\/i>: A Review of the Literature"],"prefix":"10.1200","volume":"22","author":[{"given":"Alexander","family":"Liede","sequence":"first","affiliation":[{"name":"From the Women's Cancer Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA; and Centre for Research in Women's Health, Sunnybrook & Women's College Health Sciences Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth Y.","family":"Karlan","sequence":"additional","affiliation":[{"name":"From the Women's Cancer Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA; and Centre for Research in Women's Health, Sunnybrook & Women's College Health Sciences Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Narod","sequence":"additional","affiliation":[{"name":"From the Women's Cancer Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA; and Centre for Research in Women's Health, Sunnybrook & Women's College Health Sciences Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1126\/science.7545954"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1038\/378789a0"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1126\/science.8091231"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.32.12.982"},{"key":"R5","unstructured":"The U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999 Incidence . Atlanta, GA, Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute, 2002"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1086\/318181"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.576"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0045(19990801)40:3<172::AID-PROS5>3.0.CO;2-R"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1086\/302525"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1249"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1086\/302678"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1089\/10906570050501579"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.6.1480"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1598"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1038\/ng0597-17"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10155"},{"key":"R17","unstructured":"Johannesdottir G, Gudmundsson J, Bergthorsson JT, et al: High prevalence of the 999del5 mutation in Icelandic breast and ovarian cancer patients. Cancer Res 56:3663,1996-3665,"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1007\/s001090050162"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1086\/345310"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1038\/ng0596-123"},{"key":"R21","unstructured":"Friedman LS, Gayther SA, Kurosaki T, et al: Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet 60:313,1997-319,"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1997.574"},{"key":"R23","unstructured":"Thorlacius S, Sigurdsson S, Bjarnadottir H, et al: Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet 60:1079,1997-1084,"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)03300-5"},{"key":"R25","unstructured":"Haraldsson K, Loman N, Zhang QX, et al: BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease. Cancer Res 58:1367,1998-1371,"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1002\/1098-1004(2001)17:1<73::AID-HUMU12>3.0.CO;2-O"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Basham VM, Lipscombe JM, Ward JM, et al: BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. Breast Cancer Res 4:R2, 2002","DOI":"10.1186\/bcr419"},{"key":"R28","unstructured":"Ottini L, Masala G, D'Amico C, et al: BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: A population-based study in Italy. Cancer Res 63:342,2003-347,"},{"key":"R29","unstructured":"Goggins M, Schutte M, Lu J, et al: Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 56:5360,1996-5364,"},{"key":"R30","unstructured":"Lal G, Liu G, Schmocker B, et al: Inherited predisposition to pancreatic adenocarcinoma: Role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Cancer Res 60:409,2000-416,"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1136\/gut.50.5.653"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19990730)82:3<325::AID-IJC3>3.0.CO;2-G"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10693"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.02-0026"},{"key":"R35","unstructured":"Csokay B, Udvarhelyi N, Sulyok Z, et al: High frequency of germ-line BRCA2 mutations among Hungarian male breast cancer patients without family history. Cancer Res 59:995,1999-998,"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.1086\/513891"},{"key":"R38","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.1320570102"},{"key":"R39","doi-asserted-by":"publisher","DOI":"10.1038\/ng1095-198"},{"key":"R40","unstructured":"Thompson D, Easton D: Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomarkers Prev 11:329,2002-336,"},{"key":"R41","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.18.1365"},{"key":"R42","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.18.1358"},{"key":"R43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199705153362001"},{"key":"R44","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.15.1310"},{"key":"R45","doi-asserted-by":"publisher","DOI":"10.1086\/302853"},{"key":"R46","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0045(19990601)39:4<280::AID-PROS8>3.0.CO;2-F"},{"key":"R47","unstructured":"Sinclair CS, Berry R, Schaid D, et al: BRCA1 and BRCA2 have a limited role in familial prostate cancer. Cancer Res 60:1371,2000-1375,"},{"key":"R48","unstructured":"Gayther SA, de Foy KA, Harrington P, et al: The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer: The Cancer Research Campaign\/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators. Cancer Res 60:4513,2000-4518,"},{"key":"R49","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.39.7.457"},{"key":"R50","doi-asserted-by":"publisher","DOI":"10.1038\/ng0197-103"},{"key":"R51","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/6.1.53"},{"key":"R52","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)91578-4"},{"key":"R53","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0215(20001201)88:5<778::AID-IJC15>3.0.CO;2-N"},{"key":"R54","doi-asserted-by":"publisher","DOI":"10.1038\/ng1096-185"},{"key":"R55","doi-asserted-by":"publisher","DOI":"10.1086\/301903"},{"key":"R56","doi-asserted-by":"publisher","DOI":"10.1038\/ng0596-120"},{"key":"R57","doi-asserted-by":"publisher","DOI":"10.1038\/nm1196-1179"},{"key":"R58","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/95.3.214"},{"key":"R59","unstructured":"Murphy KM, Brune KA, Griffin C, et al: Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: Deleterious BRCA2 mutations in 17%. Cancer Res 62:3789,2002-3793,"},{"key":"R60","unstructured":"Berman DB, Costalas J, Schultz DC, et al: A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals. Cancer Res 56:3409,1996-3414,"},{"key":"R61","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600562"},{"key":"R62","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03540360065034"},{"key":"R63","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2003.50044"},{"key":"R64","doi-asserted-by":"publisher","DOI":"10.1086\/342506"},{"key":"R65","doi-asserted-by":"publisher","DOI":"10.1086\/318787"},{"key":"R66","doi-asserted-by":"publisher","DOI":"10.1038\/ng1096-188"},{"key":"R67","doi-asserted-by":"crossref","unstructured":"Liede A, Metcalfe K, Hanna D, et al: Evaluation of the needs of male carriers of mutations in BRCA1 or BRCA2 who have undergone genetic counseling. Am J Hum Genet 67:494,2000-504,","DOI":"10.1086\/316907"},{"key":"R68","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg164"},{"key":"R69","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejhg.5200668"},{"key":"R70","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.10.2135"},{"key":"R71","unstructured":"Breslow NE, Day NE: The design and analysis of cohort studies , in Davis W (ed): Statistical Methods in Cancer Research (vol II). Lyon, France, International Agency for Research on Cancer, 1987"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2004.05.055","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:25:10Z","timestamp":1653510310000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2004.05.055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2,15]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,2,15]]}},"alternative-id":["10.1200\/JCO.2004.05.055"],"URL":"https:\/\/doi.org\/10.1200\/jco.2004.05.055","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,2,15]]}}}